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"The highest happiness of 
man is to have probed 
what is knowable, and to quietly revere what is unknowable. • 
- Johann Wolfgang von Goethe 
Patient Safety 
For healthcare providers, patient safety has always been a 
concern and a priority. The 19991nstitute of Medicine report 
took a critical look at safety in the American hospital system 
and found it lacking. Since then, numerous organizations and 
medical groups have united around a common set of principles 
summarized here: 
)> A safety conscious environment - a nonpunitive culture 
that encourages reporting healthcare errors, focusing on 
system failures rather than individual culpability 
)> Data analysis - comprehensive review of information 
reported to ensure that we reduce the risk of reported 
events recurring 
)> Confidentiality - protection for patients, healthcare 
professionals and healthcare organizations is essential for 
any reporting system 
)> Information sharing - reporting systems should exchange 
information and foster collaboration in the search for 
solutions 
)> Legal status of reported information - the lack of federal 
immunity for information submitted will deter effective 
reporting mechanisms. 
The debate now in Congress is whether to create federal 
legislation mandating reporting of medical errors versus a 
focus on reducing healthcare errors at the local level. 
Secretary of Health and Human Services, Tommy Thompson, 
has created a Patient Safety Task Force to address medical 
Medical Liability Matters errors. 
Page 10 
News from CEDS 
Pages 11 to 14 
Therapeutics at a Glance 
Pages 15 to 19 
The medical staff endorses this effort, and we at LVH have 
taken a major step forward in utilizing available technology to 
reduce medical errors. It is called computer assisted physician 
order entry (CAPOE), capably led by Dr. Don Levick, chair of 
the LVPHO Information Services Committee. As reported in 
Valley Preferred News (6/01}, this group has also "looked at a 
(Continued on Page 2) 
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variety of electronic applications, including office management 
software, prescription writing modules and health information 
sites." 
How about ChanneiHealth, a secured webstte accessed via 
the Internet? It features patient information access and clinical 
reference material- now available in your office through the 
web- access limned to this planet. (Call LVH Information 
Services at (610) 402-8303.) 
As Rich Boorse is fond of saying, "Buckle your seat belts, 
folks." We live in exciting times. Medical care is changing and 
we must change with it to provide continued quality care for 
our patients and our community. Their trust is in the balance. 
"My responsibility is to get my 25 guys playing for the name on 
the front of their uniform and not on the back." 
-Tommy Lasorda 
Coach, LA Dodgers 
Malpractice in Pennsylvania 
First the good news -
Newswire item: The Pa. Senate unanimously passed a CAT 
Fund Reform Bill. 
SB 556, sponsored by Sen. Edwin Holl (R-Montgomery), would 
transfer responsibility for the state's Medical Professional 
Liability Catastrophe Loss Fund (CAT Fund) to an independent 
authority with the power to issue bonds to cover liabilities as 
the CAT fund is phased out over six years, placing all medical 
liability coverage under private insurance. The bill now goes to 
the House, where it is expected to be referred to the House 
Insurance Committee. The House version of the bill (HB 1802} 
is derived from the joint agreement on the CAT Fund's phase-
out between the Pennsylvania Medical Society and the 
Hospital & Healthsystem Association of Pennsylvania. 
(Pennsylvania Medical Society, June 19, 2001) 
This is clearly a start. Resolution of the lingering CAT Fund 
problem, along with limitations on frivolous lawsuits, is very 
encouraging. We should thank our state senators for their 
support in making this happen. 
Then, there's the bad news -
We still have a long way to go, and malpractice premiums in 
this Commonwealth are still exceedingly high (40 to 70% 
higher than in surrounding states}. Get in this game. As Dr. 
Carol Rose (a practicing anesthesiologist from Pittsburgh and 
current president of Pennsylvania Medical Society) put it, "I 
believe and I belong." Expect the Pennsylvania Trial Lawyers 
Association to fight all tort reform efforts with self-righteous 
indignation. They continue to defend the costly present tort 
system as the protector of public safety, but there's one major 
flaw in their argument The present tort system is simply not 
working! Think about it! The problem is not getting better; it's 
getting worse. The public deserves a different and better 
system of addressing medical errors, one that does not siphon 
off precious medical resources to subsidize our legal brethren. 
Newswire item: Pottstown Memorial Medical Center Is 
Having Difficulty Securing Medical Malpractice Liability 
Excess Coverage. 
John Buckley, president and CEO of the western Montgomery 
County hospital, said that Pottstown Memorial had a 78 percent 
increase in medical liability premiums for fiscal 2002, that the 
hospital's institutional excess coverage-which insures the 
hospital against awards in excess of$1.2 million-hasn't been 
renewed, and that he can't find any insurers willing to provide the 
coverage because of higher-than-average jury awards in 
malpractice cases in southeastern Pa.,reported the Business 
Journal. (Philadelphia Business Journal, July 9, 2001) 
"In basketball, you can be the greatest player in the world and 
Jose evety game, because a team will always beat an 
individual. • 
-Bill Walton, professional basketball player 
Graduate of UCLA system 
HCFA is Dead (just when I was getting used to it), long live 
CMS (I guess). 
Newswire item: The Health Care Financing Administration 
(HCFA) has been renamed as the Centers for Medicare 
and Medicaid Services (CMS). 
The Bush administration announced the name change of the 
agency that runs Medicare and Medicaid in the hope of 
repairing its image as a bureaucratic behemoth, while 
Secretary of Health and Human Services Tommy Thompson 
said the change symbolized his commitment to improving the 
agency's services to beneficiaries, doctors, hospitals and other 
health care providers, reported the New York Times. 
Thompson announced that CMS will be reorganized into three 
divisions: the Center for Beneficiary Choices, which will 
provide information to Medicare patients in private health 
(Continued on Page 3) 
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plans; the Center for Medicare Management, which will run the 
traditional fee-for-service version of the insurance program; 
and the Center for Medicaid and State Operations, which will 
handle Medicaid and the State Children's Health Insurance 
Program, the Washington Post noted. (New York Times, June 
15,2001) 
"To be a champion, you have to believe in yourself when 
nobody else will. • 
- Sugar Ray Robinson 
Professional Attire- As healthcare professionals in a premier 
academic community hospital, we should project an image with 
our dress that indicates we take our mission seriously. Overly 
casual attire (usually on weekends) may be inappropriate in 
some patient care settings. We respectfully ask the medical 
staff to use their good judgment in this regard. 
"For the great majority of mankind are satisfied with 
appearance, as though they were realities and are often more 
influenced by the 
things that seem than by those that are." 
- Niccolo Machiavelli 
"Time management is an unfamiliar concept to most 
physicians. In medical school and during residency, 
physicians are never taught time management skills. As a 
result, there is tremendous variability in the efficiency of 
physicians. Almost all physicians can benefit from gaining 
better time management skills ... my research had revealed that 
all physicians have individualized patterns of inefficient and 
efficient use of time. Once practitioners recognize their own 
patterns, they can make major changes in how they utilize their 
time." 
-Marshall Zaslove, MD 
Psychiatrist, author and productivity consultant 
Beginning with this issue, a new feature - "Spotlight on ... " 
-- will be included in Medical Staff Progress Notes. Every 
month, this new feature will highlight a member of the Medical 
Staff. This month's feature will include a Spotlight on John E. 
Castaldo, MD (see article on Page 6). 
Edward M. Mullin, Jr., MD 
President, Medical Staff 
News from Central Scheduling 
On Monday, July 2, Central Scheduling in the Diagnostic Care 
Center at Cedar Crest & 1-78 began scheduling tests and 
procedures performed in the hospital Radiology Departments 
at Cedar Crest & 1-78 and 171h & Chew (Ultrasound, CT Scans, 
and FLUORO). These are in addition to those tests in Pre-
admission Testing, Non-invasive Cardiology, NEURO, PULM, 
Nuclear Medicine and the Sleep Disorder Center currently 
being scheduled by the Central Scheduling Department. 
lnterventional Radiology (arteriograms, etc.) will continue to be 
scheduled by the Radiology Department at (61 0) 402-8080 
until later this fall. 
Physician offices that are scheduling patients for radiology 
procedures are reminded that there is still a separate phone 
number to schedule tests at Lehigh Valley Diagnostic Imaging 
(LVDI). If LVDI cannot accommodate the patient in a timely 
manner or due to insurance plans, the exam may be 
scheduled at 17th & Chew or Cedar Crest & 1-78 (based on the 
urgency of the study). 
Depending on the insurance plan that a patient has, most of 
the procedures performed in Radiology require a referral and 
an authorization number from the managed care company. In 
addition, all tests are required to have a written order 
(prescription) which includes appropriate signs and symptoms 
as a reason for the test. In order to facilitate the patient's 
experience when they arrive at the hospital, the scheduling 
clerk will remind the office staff or the patient when the test or 
procedure is scheduled, that the above is required. In order to 
streamline the process from physician offices and decrease 
phone calls back and forth, please communicate the 
prescription and the referral and/or authorization numbers via 
phone or fax to Central Scheduling prior to the scheduled test. 
Patients who arrive without a referral, authorization, and/or 
prescription, will unfortunately have to be rescheduled. In an 
effort to avoid this from occurring, a scheduling clerk will call 
the physician's office 48 hours in advance to secure any 
necessary information that is still missing. 
The number for Central Scheduling is (610) 402-TEST (8378). 
The fax number is (610) 402-8708. For physician office 
convenience, Central Scheduling is open Monday through 
Friday from 7 a.m. to 7 p.m. 
If you have any questions, comments or concerns, please 
contact Lisa Coleman, Director of Support Services, at (610) 
402-8066, or Mark Holtz, Vice President of Operations, at 
(484) 884-4710. 
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Required Ethics Education 
The FDA will be requiring research ethics education in the near 
future for all investigators conducting studies or submitting new 
protocols. Listed below is a website that you may ~ish to visit 
and get a headstart on this requirement by completmg the 
training. The IRB Board members have already done this. 
Those who have said it "wasn't that bad," "was actually 
interesting," and "was fun." 
If you do choose to complete the training, please forward your 
completed certificates (you print them out yourseln to 
Bernadette Glenn at Health Studies Research, 17th & Chew, 
Suite #6-T -38. All investigators will eventually need to have 
documentation on file in the IRB Office. 
The following is the OHRP web site: 
http://ohrp.osophs.dhhs.gov/ 
When arriving at the website, click on: 
1. Educational Materials 
2. Then, Tutorials "Training Modules for Assurances" 
3. Individual must login to begin 
There are three tutorials: 
1. Federal Regulations & Institutional Responsibilities 
2. Investigator Responsibilities & Informed Consent 
3. Human Protections Program Administration & IRB 
Responsibilities 
If you have any questions regarding this issue, please contact 
Bernadette Glenn at (610) 402-2529. 
Coding Tip of the Month 
When a patient is admitted with a lower extremity 
ulcer and also carries a diagnosis of Diabetes and 
Peripheral Vascular Disease, the coder looks for 
documentation in the record that would link (cause 
and effect) these.conditions. To know this 
information helps to assign accurate DRGs and also . 
assures appropriate Hospital reimbursement. 
News from CAPOE Central 
We have been live with CAPOE for approximately one month. 
Overall, it has gone very well. I would like to thank the Medical 
Staff for their patience with the new system. The majority of 
the feedback on the TTU has been positive -- it appears that 
most physicians appreciate being able to view Vital Signs, I 
and O's, labs and medication administration all on one screen 
(the Viewer). 
The Trauma Team (attendings and PA's) has shown incredible 
patience and commitment toward making CAPOE work. The 
PA's especially have been great to work with and have 
provided invaluable feedback. The CAPOE team has already 
made changes to the user interface based on their co~~ents. 
The Pharmacy and Nursing staffs have had to learn s1gmficant 
new work processes despite being understaffed. They have 
done remarkably well, and I would also like to thank them and 
acknowledge their efforts. 
Several questions have come up regarding use of the system. 
We are trying to respond to these issues in various venues, 
including here in Medical Staff Progress Notes. Help is 
available by calling the CAPOE Hotline at (610) 402-8303, 
option #9. There is on-screen help accessible through the 
"HELP" menu at the top of the Lastword screen. Choose 
"CAPOE HELP," and you will be taken to a web page where 
you can access on-line versions of the Lastwo~ and. CAPOE 
manuals, a section on "Frequently Asked Questions, and an 
index of "Tips and Tricks." 
Several physicians have commented that the "Viewer" is 
difficult to read, especially on the handheld devices. The 
problem is that the size of the print (font) on the viewer is too 
small or difficult to see. However, you can change the 
typeface and size in the Viewer. When in the Viewer, go to the 
VIEW menu at the top of the window. There are choices to 
increase the font size (BIGGER FONT), which will 
incrementally increase by the font size; and CHOOSE FONT, 
which allows you to choose the font and the size. NOTE: the 
changes are specific for each device or computer, and do not 
stay with the user. 
Physicians have also asked to be able to print their census 
the same way as before, sorted by bed number and with th~ 
age and diagnosis. This can be easily done. From the Mam 
Physician Base Screen, type "GCN" in the command field (the 
open field at the bottom of the screen). This will brin~ up your 
group census. Click on the PRINT CENSUS bu~on ~n the 
lower right hand comer, and the census sheet Will pnnt out to 
the printer assigned to that computer. 
We will continue to respond to the questions and concerns of 
the Medical Staff and other users. Everyone is committed to 
making this a success. Please contact me if you would like 
more information or have specific concerns. 
Don Levick, MD, MBA 
(484) 884-4593 
(610) 402-5100 7481 (pager) 
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INBOX Alerts & Reminders •• You Have 
Orders to Sign 
The IN BOX- Alerts & Reminders portion of the Physician 
Base screen in Lastword serves as a reminder to sign orders. 
Figure 1 - Physician Base Screen in Lastword showing 
INBOX location 
In an instance where a PA or medical student enters an order 
for a patient, or the attending physician calls in a telephone 
order, the CAPOE system requires the electronic signature of 
the attending physician for the order. The You Have Orders to 
Sign reminder appears in the INBOX window when these types 
of orders generate. 
To access unsigned orders, click on this alert located in the 
INBOX window, then click on the Select button located at the 
bottom of the window. The Sign Orders window opens (see 
Figure 2). A list of outstanding orders is selected for you to 
sign. 
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Figure 2 - Orders to Sign 
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Click on the Review Selected Order Detail button to review 
individual order details. 
Click on the Review Audit button to review an Order Audit 
Trail (i.e., the date/time an order was entered into the system). 
All orders are selected by default, and can be unselected by 
clicking on the appropriate check boxes located to the left of 
each order. Click the Sign Selected Orders button to sign the 
orders you selected. The orders are now signed in the system 
just as you would have initialed written orders. 
The INBOX- Alerts & Reminders feature also provides alerts 
for abnormal lab results, new ancillary results, for whom you 
are offering coverage, and the physician(s) covering for you. 
To learn more about these features, please take a moment 
and review the on-line documentation for Lastword Version 
4.1.7. Both the CAPOE and Non-CAPOE Physician User 
Guides can be found on the LVHHN Intranet under the 
Resources heading Lastword for Physicians. 
If you wish to obtain a paper copy of one of these documents, 
please contact Lynn Corcoran-Stamm at (610) 402-7053, or 
Carolyn K. Suess, RN, at (610) 402-7052. 
Phys·ician Parking Duri.ng the 
· Allentown Fair . 
It's that time of the year again . . . 
time to begin preparation for the 
Great Allentown Fair. As in past 
years, parking changes will be made 
for physicians and housestaff at fih 
& Chew. Beginning Tuesday, . 
August 14, through Monday, · 
September 1 0, parking for physicians 
and housestaffwill be·reassigfled to 
Lot #4 .(No.rth:west Street} and Lot· 
#5 (Gordon Street). PhysiciaD and 
housestaff photo IPs will be 
programmed to access these areas 
during this period. 
lfyou have any questions regarding 
this issue, please contact louis 
Geczi in SecuritY at(610) 402~2986. 
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'"'J> <1~;. Spotlight on ... 
-1'1 '\@ 
~~ 
John E. Castaldo, MD 
Born in Mount Vernon, N.Y., Dr. Castaldo is a graduate of 
Dartmouth College, Hanover, N.H., where he received a 
Bachelor of Arts degree. He received his medical degree from 
Dartmouth Medical School, and completed his internship 
followed by a three-year residency at Dartmouth-Hitchcock 
Medical Center. Following his residency, Dr. Castaldo joined 
the Lehigh Valley Hospital Medical Staff in 1983. He is a 
member of the Department of Medicine, Division of Neurology, 
and is in practice with Lehigh Neurology. He was recently 
named Chief of the Division of Neurology. 
As a seasoned member of the hospital's Medical Staff, Dr. 
Castaldo held the prestigious position of Medical Staff 
President from 1995 to 1996. He also served as a member of 
the hospital's Board of Trustees from 1993 to 1998. Dr. 
Castaldo has also served as a member on numerous 
committees including: Ethics Committee, Resident Review 
Committee, Institutional Review Board, Medical Executive 
Committee, Performance Improvement Council, Clinical Case 
Review Committee, Hospital-Wide Quality Assurance 
Committee, Functional Planning Steering Committee, Hospital 
Staff Development Advisory Committee, and the Nomination 
Committee for the Board of Trustees. 
In 1997, Dr. Castaldo was awarded the Hahnemann School of 
Medicine - Dean's Special Award for Excellence in Clinical 
Teaching. In 1999, he was appointed Professor of Clinical 
Medicine at Penn State University/Milton S. Hershey Medical 
Center. 
As the Director of Neuroscience Research, Dr. Castaldo has 
been extensively involved in a number of research studies 
including LOVAR - Lowering of Vascular Atherosclerotic Risk 
Trial (see article on Page 7). In addition, he has co-authored 
numerous journal articles and book chapters. 
Dr. Castaldo and his wife, Nancy, have three sons- David, 
Mark and Nick. In his spare time, he enjoys bike riding, 
woodworking, and playing guitar. 
In conclusion, Dr. Castaldo has the following "words of 
wisdom" to offer to the Medical Staff: 
1. Do the Right Thing, which is often not easy, expedient or 
inexpensive. 
2. Listen more; speak less - so you'll know the right thing 
when you see it. 
3. Make time for relationships every day. Nurture and 
cherish them. 
4. Aspire to achieving excellence if only in small incremental 
steps. 
5. Bring more to the table than you take away- and your 
table will be always bountiful. 
6. Be humble. Respect those more experienced than you. 
7. Fix things and people you find broken as much as is 
possible. 
8. Accept and embrace diversity in all its forms. 
9. Remember that compromise is a pillar of collaboration; not 
a fall back position. 
10. Preserve and inspire enthusiasm for the greater good. 
2001 United Way Campaign 
Annually, nearly 1,300 Lehigh Valley children and 
youth require tax-support services totaling $29.2 
million- an average of $22,500 per child. However, 
with help from you .and others like you, the average 
cost for a child served by the Boys and .Girls Clubs is 
$300; the Learning Club : $1, 130; and after-school' . 
programs -.$510. 
Please plan to Join your colleagues in· partiqipating in 
this.year's 2001 LVHHNUnited Way Campaign, 
which wiJI kick-off on August 16. Thi.s year's goal is 
a lofty one: to raise·$257;783 and to increase ·, 
participation by 25% to 1,611· donors. · 
Physicians and staff will receive a. personalized 
pledge and designation form early in Septe111ber. :It 
is hoped that you will become part of the LVHHN 
United Way Team this year with your participation. 
Remember TEAM = Together· Everyone Achieves. 
More. 
Watch for more information in next month's issue of 
Medical Staff Progress Notes. If you have arl'y · 
questions, please contact one of the campaign co-
chairs -'·Betty Anton, Director of VOlunteer Services, 
at(610) 402-8897, or Don Hougendobler, Director of 
Safety/LVH-M Housekeeping, at (484) 884-2293 .. 
,. 
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KePRO Project: Admission vs. 
Observation Stay 
KePRO, the Peer Review Organization for Pennsylvania, is 
responsible for monitoring the quality care of Medicare 
beneficiaries. KePRO initiated a project evaluating the 
appropriateness of hospital one-day stays with a focused 
review on specified DRGs. The review was primarily 
educational, but also enables KePRO to identify causes of 
payment errors. No approval or denial determinations were 
made. This review provides an opportunity to make necessary 
changes prior to having a monetary effect. 
Among the short stay population, KePRO indicated that there 
was a lack of severity of illness and the provision of few acute 
care services. The following summarizes their findings based 
on cases reviewed for both Lehigh Valley Hospital and Lehigh 
Valley Hospital-Muhlenberg: 
DRG % of Cases Not Meeting 
Admission Criteria 
DRG 243 Medical Back 67% 
Problems 
DRG 065 Oysequilibrium 91% 
DRG 015 Trans Ischemic 84% 
Attack 
DRG 320 Urinary Tract 76% 
Infections 
Overall 83% 
A LVHHN physician advisor conducted a similar internal review 
for DRG 143: Chest Pain, and found 79% of the cases did not 
meet criteria. 
Based on these results, KePRO suggests that patients failing 
to meet admission criteria should have been treated in an 
outpatient setting or observation. Observation may occur 
anywhere in the hospital, i.e., in the Emergency Department, 
patient floor, any care unit appropriate to the services being 
rendered, where the need is clearly documented. To avoid 
confusion, KePRO recommends that physicians use the 
language "Place in Observation" in the medical chart. 
If you are unsure, try observation first. It is always possible to 
admit the patient if necessary. 
Payment for observation is currently bundled into the Medicare 
prospective payment for outpatient services with which 
observation is associated. Physicians are reimbursed through 
the Medicare fee schedule. However, Medical Assistance 
does not recognize observation status. The patient is viewed 
as an outpatient and the procedure is billed. 
If you have a question related to observation status, please 
contact Susan Lawrence, Administrator of Case Management, 
at (610) 402-1760. 
The Lowering of Vascular 
Atherosclerotic Risk (LOVAR) Study: 
Is a pound of prevention worth a ton of 
cure? 
LOVAR is an outcomes-based research initiative designed to 
assess the cost-effectiveness of cardiovascular, 
cerebrovascular and peripheral vascular disease case 
management of patients. It is designed to work with 
community physician offices to enhance prevention strategies 
and promote durable lifestyle changes in patients at risk for 
vascular ischemic events. 
The study population consists of Lehigh Valley Hospital (LVH) 
patients age 39 to 79 who have documented symptomatic 
vascular disease (within the last six months) and have at 
least two modifiable risk factors such as diabetes, 
hypertension, obesity, high fat diet, smoking, sedentary living, 
hyperlipidemia, or exhibit a high degree of depression, hostility, 
and stress. The design of the study is a prospective controlled 
cohort consisting of 250 controls who will receive community 
standard prevention services recommended by their 
physicians and 250 cases who will receive the 12-week 
comprehensive risk factor reduction program and intensive 
coordinated case management services. The goal is to reach 
at least 500 patients in the study. To date, 450 patients have 
been enrolled in the study. 
Patients are followed for at least three years from the date they 
enter the study. Examination procedures and medical tests 
performed are within the realm of standard treatment for 
vascular disease. Participants are encouraged to see their 
own physician for regular check-ups and take medications 
prescribed by those physicians while in the study. 
At least 50 more patients are needed for the study. Physicians 
with patients exhibiting the above criteria are encouraged to 
enter them into the study. For more information about the 
study or to refer a patient, please contact John E. Castaldo, 
MD, Principal Investigator, at (610) 402-8420, or Jane M. 
Nester, MPH, MEd, Co-Principal Investigator, at (610) 402-
4088. 
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Congratulations! 
Gary S. Greenberg, DPM, Division of Orthopedic Surgery, 
Section of Podiatry, has been elected Chairman of the Council 
of Teaching Hospitals of the American Association of Colleges 
in Podiatric Medicine. Dr. Greenberg assumed this position on 
July 1. He has been on the Board of Directors of that 
organization for four years and has served as Vice Chairman 
for the past year. 
Herbert L. Hyman, MD, Division of Gastroenterology, has 
been appointed Chairman of the Advisory Board of the Chronic 
Fatigue Syndrome Research Center, New Jersey Medical 
School, Newark, N.J. 
Douglas F. Turtzo, MD, Division of Pulmonary, was recently 
elected to Fellowship in the American College of Physicians--
American Society of Internal Medicine. 
Papers, Publications and Presentations 
Kelly M. Freed, MD, Division of Diagnostic Radiology, co-
authored a paper -- "Breakthrough contrast reactions to low-
osmolar contrast media after steroid premedication" --which 
was published in the June issue of the American Journal of 
Roentgenology. This article reviewed patients who 
experienced an adverse reaction to non-ionic contrast 
following corticosteroid premedication. Typically, the 
breakthrough reaction was of similar severity to the patient's 
initial reaction, but was more severe, even life-threatening, in a 
minority of patients. In these patients, alternative examinations 
such as contrast-enhanced MRI, US, or non-contrast CT 
should be performed. 
Peter A. Keblish, Jr., MD, Division of Orthopedic Surgery, 
was an invited guest speaker at a course - "Current 
Controversies in Total Knee Arthroplasty"- held at Lennox Hill 
Hospital in New York City. Under the direction of well-known 
total joint specialist, Dr. Chitranjan Ranawat, Director of 
Orthopaedics at Lennox Hill Hospital, the course emphasis 
was on newer concepts of mobile bearing total knee 
arthroplasty. Dr. Keblish presented topics related to surgical 
approaches, patella management, and wear issues in total 
joint replacement. He also participated in a panel of experts 
on case report evaluation. 
Lester Rosen, MD, Division of Colon and Rectal Surgery, was 
the senior author of a paper titled, "Readmissions after 
Colorectal Surgery Cannot be Predicted," which was published 
in the July 2001 edition of Diseases of the Colon and 
Rectum. John J. Stasik, MD, Robert D. Riether, MD, and 
lndru T. Khubchandani, MD, all in the Division of Colon and 
Rectal Surgery, are among the co-authors. 
The methodology consisted of 249 patients who were operated 
on from July 1, 1996 to March 30, 1998. All patients who had 
an unplanned related readmission within 90 days of discharge 
from the hospital were evaluated. The incidence of unplanned 
related readmissions after 90 days was 9%, and these 
readmissions could not be predicted from the post-operative 
course. As 82% of the unplanned readmissions occurred 
within 30 days, this timeframe was deemed more suitable for 
computerized analysis. The mean interval between discharge 
from the hospital and readmission was 19 days, and the mean 
duration of hospital stay during the admission was eight days. 
The most common cause of readmission was small bowel 
obstruction. Nine of these patients required reoperation. 
Additionally, Dr. Rosen was one of the panel members who 
participated in the development and review of the American 
Medical Association Quality Care Alert on "Colorectal Cancer 
Screening and Surveillance." Dr. Rosen represented the 
American Society of Colon and Rectal Surgeons. The Quality 
Care Alert provides a synthesis of the most recent evidence 
and/or recommendations for colorectal cancer screening. The 
recommendations relate to asymptomatic individuals as well as 
to individuals who are at high risk for colorectal cancer. One of 
the newer considerations is that direct colonoscopy screening 
of average risk patients every 1 0 years is an option and is 
covered by Medicare beginning July 1, 2001. 
For additional information, contact the American Cancer 
Society at {404) 320-3333 or visit the website: www.ama-
assn.org/ama/pub/article/1616-5075.html 
MBA Program 
DeSales University is sponsoring an Open 
House/Information Session on their MBA 
Program for Physicians and MSN's. 
Classes are held at Lehigh Valley Hospital, . 
Cedar Crest & 1-78. For more information, 
you .are invited to attend the open house on 
Thursday, August:9, at 5 p.m., in Classroom 
3 at Cedar Crest & 1~ 78. 
For more information regarding the MBA 
Program, please contact Debra 
Hockenberry at DeSales University at (610) 
282-1100 Ext. 1451., 
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" Who's New 
The Who's New section of Medical Staff Progress Notes 
contains an update of new appointments, address changes, 
resignations, etc. Please remember to update your directory 
and roloclexes with this information. 
Medical Staff 
Address Changes 
Jeffrey B. Alpern, DO 
P.O. Box 5344 
Bethlehem, PA 18015 
(610) 758-9432 
Fax: (610) 758-9433 
Jon E. Brndjar, DO 
111 E. Harrison Street 
Suite 3 
Emmaus, PA 18049-2916 
(610) 965-1900 
Fax: (610) 965-2900 
Debra E. Cressman, MD 
Thomas E. Yablonski, MD 
215 N. Best Avenue 
Walnutport, PA 18088-1204 
(61 0) 760-7044 
Fax: (610) 760-8587 
Practice Disassociation 
Nancy A. Mao, MD 
(No longer associated with Drs. Bub and Young Family 
Medical Center) 
Please forward all correspondence to: 
1251 S. Cedar Crest Blvd. 
Suite 305-D 
Allentown, PA 18103-6205 
Practice Name Change 
From Harwick, Papola and DeDic Associates 
To Harwick and DeDio Associates 
Pager Number Change 
Barry J. Hennessey, DO 
(610) 402-5100 8172 
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Medical Liability Matters 
(This information is being provided to you by Robert X. Murphy, Jr., MD, OMSS Representative) 
First Two Reform Bills Pass Senate Unanimously 
CAT Fund Privatization: With the ink not yet dry on tobacco settlement and budget measures, 
legislators in June dug into medical liability and CAT Fund reform initiatives. Amid a flurry of eleventh-
hour activity on June 19th, the Senate passed SB 556, the Medical Society/Hospital & Healthsystem 
Association of Pennsylvania (HAP) proposal to privatize the CAT Fund. The only amendment was a 
non-controversial one to aid CAT Fund employees who would stand to lose their jobs with privatization. 
Swift passage of SB 556 was facilitated by the Society's continuous meetings and negotiations with 
Representative Nick Micozzie (R-Delaware), chair of the House Insurance Committee, and with 
Senator Edwin G. Hall (R-Montgomery), key sponsor of the bill. The bill has been referred to the House 
Insurance Committee. As detailed in the Joint Medical Society/HAP statement, SB 556 would phase 
down the Fund within six years by gradual increases in the primary limits and corresponding decreases 
in CAT Fund limits. Transfer of responsibility to the private sector would be financed through a bond 
with an annual assessment on health care providers to pay principal and interest costs. 
In the House, Representatives Micozzie and Tony DeLuca (D-AIIegheny) this month introduced HB 
1802, a mirror of SB 556. Hearings are expected this summer to resolve differences that remain with 
the academic health centers. Either bill could carry the Society's CAT Fund privatization proposals 
forward. 
Frivolous Lawsuit Abuse: Close on the heels of the CAT Fund privatization measure, a State Society-
supported bill to curb frivolous lawsuits, Senate Bill406, passed in the Senate 47-0. Following its 
unanimous passage, Senator Robert J. Thompson (R-Chester) declared SB 406 the "first step in 
medical liability reform." Thompson and Senator James Gerlach (R-Chester) crafted the bill, which 
would create a new cause of action for the filing of a frivolous lawsuit, and would allow those subject to 
such a suit to immediately seek damages from the frivolous litigant while the frivolous suit is pending. 
"Current state law requires that you win your suit before you can file a separate suit claiming 
frivolousness," Thompson said. "This is a time-consuming and costly process .... If enacted, this 
measure will be a deterrent to those people who would file unwarranted suits that clog our legal system 
and are costly to everyone." Senator Gerlach noted in a statement, "Along with the Senate's recent 
passing of the medical CAT Fund restructuring, this is another positive step to addressing the medical 
malpractice crisis and the burden frivolous lawsuits are placing on the legal system." 
Remember: These bills are only the beginning! The Society is working hard over the summer on a 
series of tort reform measures to be moved forward in the fall. Each measure will be part of the 
Society's overall strategy to design a complete medical liability reform package for Pennsylvania. 
How Can You Help? 
Physician grassroots support is vital over the summer to continue the momentum of medical liability 
reform into the fall session. · 
Both bills-58 406 and SB 556-were passed unanimously by the Senate. These legislators have voted 
on your behalf-the physician community-to advance proposals to begin medical liability reform in 
Pennsylvania. Let's thank them for their work and their support. 
Contact your state senator to thank him or her for voting for the CAT Fund reform bill, SB 556, and the 
frivolous lawsuit bill, SB 406. For information on how to contact your legislator, go to 
www.pamedsoc.org <http://www.pamedsoc.org/> and click on "advocacy," or call the Liability Reform 
Action Center at 1-800-566-TORT (8678). 
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August 2001 
NEWS FROM THE LffiRARY. 
OVID Instruction. 
For personal instruction in the use of'OVID~s MEDLINE 
and its other databases, contact Barb Jobst at'610-402-
8408. 
New Library Publications 
cc & 1-78 
"COLOR ATLAS OF BURN CARE: A COMPANION TO 
TOTAL BURN CARE" Author: D. Herndon 
"DIABETIC NEUROPATHY." 2nd edition 
Author: P. Dyck 
17 and Chew Streets 
"DENTISTRY FOR THE CHILD AND ADOLESCENT." 1h 
edition Author: R. McDonald 
"RAPID INTERPRETATION OF EKG's: AN INTERACTIVE 
COURSE." 6th edition Author: D. Dubin 
Muhlenberg 
"SPORTS INJURY MANAGEMENT." 2nd edition 
Author: M. Anderson 
"GROSSMAN's CARDIAC CATHETERIZATION. 
ANGIOGRAPHY. AND INTERVENTION." 6th edition 
Author: D. Bairn. 
Computer-Based Training (CBT): 
Computer Based Training (CBT) programs are available for 
L VHHN staff. Topics covered by the CBT programs include: 
Access 2.0 Power-Point 4.0 
Windows NT 4 Word 97 
Excel 97 Access 97 
PowerPoint 97 Lotus 1-2-3 Millennium 
WordPerfect 8 E-mail GUI 
PHAMIS LastWord Inquiry Only commands 
1 
CBT programs replace the instructor-led classes previously 
held at Lehigh Valley Hospital. A proctor will be in the room 
with the learner while he/she takes the CBT, but the learner 
will control the pace and objectives of the learning. 
Computer Based Training takes place in Suite 401 of the John 
& Dorothy Morgan Cancer Center (the computer training 
room) and in the Muhlenberg Hospital Center computer 
training room (off the front lobby). The schedule of 
upcoming dates is as follows: 
CBT sessions for JDMCC, suite 401 are as follows: 
August 7, 8 am - Noon 
September 18, Noon- 4pm 
October 9, Sam- Noon 
November 13, Noon - 4pm 
December 18, Noon- 4pm 
Sessions at MHC, I.S. Training room are as follows: 
July 17, Noon-4pm 
September 11, Noon- 4pm 
November 20, Noon - 4pm 
Twelve slots are available for each session. 
To register, please contact Suzanne Rice via e-mail or at 610-
402-2475 with the following: 
date of session 
second date choice 
department 
phone number 
You will receive an e-mail confirming your choice within two 
business days. If you have any questions, please contact Craig 
Koller at 610-402-2413 or through e-mail. 
Nursing Programs 
CRITICAL CARE COURSE/INTERNSHIP 
Program Coordinator: Edith Gray, MSN, Ed. Specialist 
Phone: 610-402-2348 I Pager 610-830-6019 
CEDS 610-402-2277 
************************************************ 
DAY 1 - CARDIOVASCULAR 
Tuesday, August 7, 2001, SON Aud, 17th/Chew 
07 45 Registration 
800 Intro to Course Objectives & History of Critical Care 
Nursing and AACN 
Applied Cardiovascular Physiology Cardiovascular 
Pathophysiology & Caring for Patients with: 
-Hypertensive Crisis 
- Heart Failure and Pulmonary Edema 







Cardiac Rehabilitation & Patient Teaching 
Panel Discussion 
************************************************** 
DAY 2 - CARDIOVASCULAR 
Wednesday, August 8, 2001, SONRoom#900, 17th/Chew 
745 Registration 
800 Cardiac Pacemakers: Temporary & Permanent 
12LeadECG 





DAY 3- PULMONARY/MECHANICAL VENTILATION 
Thursday, August 16,2001, JDMCC Classroom #8 3rd Floor 
0745 Registration 
0800 Pulmonary Assessment 
Acid Base Balance 
Concepts of Oxygenation 
Oxygen Therapy and Airway Management 
Principles of Mechanical Ventilation 
Advanced Mechanical Ventilation Concepts 
*************************************************** 
DAY 4- PULMONARY/MECHANICAL VENTILATION 
Friday, August 17,2001, SON Aud, 17th/Chew 
07 45 Registration 
0800 Weaning of Ventilatory Dependent Patient Carino for 
Patients With: . 
0 
-ARDS 
- Respiratory Failure 
-COPD 
2 
- Status Asthmatics 
- Pulmonary Embolism 
Care of the Thorocotomy Patient, Chest Tube 
Management and Heimlich Valve 
Care of the Patient Rec~iving Neuromuscular 
Blockade and Use ofPNS 
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Care of the Immunologically Compromised Patient 
************************************************** 
DAY 5 -HEMODYNAMIC MONITORING 
Monday, August 20, 2001, EMI, 2166 S. 12th St. 
07 45 Registration 
0800 Caring for the Cardiovascular Patient Requiring 
Antiarrhythmics and Vasoactive Medications 





-Invasive BPI A-Lines 
-CVP 
Workshops/Case Studies with Simulator 
Pressure Monitor Lines 
Medications Calculations 
************************************************* 
DAY 6 -NEUROSCIENCES 
Thursday, September 6, 2001, SON, Aud, 17th/Chew 
07 45 Registration 
0800 Neurological Anatomy and Physiology 
Neurological Assessment 
Spinal Cord Anatomy and Physiology and 
Spinal Cord Assessment 
CSF Circulation and Principles of ICP Monitoring 
Central Nervous System Infections 
Space Occupying Legions and 
Spinal Cord Tumors 
Nursing Management of the Patient with Seizures 
Neurological Hemorrhages 
Caring for Patients with Strokes 
************************************************** 
DAY 7 - GASTROINTESTINAL 
Friday, September 7, 2001, SON, Aud, 17th/Chew 
07 45 Registration 
0800 Nutritional Management in Critical Care Patients 
Alterations in GI Tract -- Anatomy and Physiology, 
Assessment 
Caring for Patients with: 
- Hepatic Failure/Cirrhosis 
- Acute Pancreatis 
- Gastrointestinal Bleeding/Hemorrhages 
- Coagulopathies 
- Multiple Organ Dysfunction Syndrome 
- Multiple System Failure 
**************************************************** 
DAY 8 -RENAL/ENDOCRINE 
Monday, September 24, 2001, SON Room #900, 17th/Chew 
07 45 Registration 
0800 Caring for Patients with Fluid and Electrolytes I 
Imbalances 
Renal Assessment/Renal Failure 
Organ and Tissue Donation 
Renal Transplant 
Diabetes Insipidus/SIADH 
Caring for Patients in a Metabolic Crisis of 
Diabetes Metlitus - DKA/HHNS 
************************************************** 
DAY 9 -NEEDS OF MULTI-SYSTEM CRITICAL CARE 
PATIENT 





- Cardiogenic Shock 
- Distributive Shock 
- Hypovolemic Shock 
- Neurogenic Shock 
Caring for the Patient with Heart Failure and 
Pulmonary Edema 
Care of the Post-Anesthesia Patient in Critical Care 
Epidural Analgesia/Neuromuscular Blockade 
Pulmonary Positioning 
Caring for the Patient with Peripheral Vascular 
Disease 
- Carotid Stenosis 
-Aneurysms 
--Thoracic 
-- Abdominal Aortic Aneurysms 
Assessment and Nursing Management of the Patient 
with Peripheral Vascular Disease 
Degenerative Disease of the Nervous System 
-Multiple Sclerosis- Gullian Barre' Syndrome 




DAY 10- HOLISTIC CRITICAL CARE ISSUES 
Monday, October 1, 2001, SON Aud 17th/Chew 
0745 Registration 
0800 Ethics in Critical Care 
Risk Management in Critical Care 
Sleep Deprivation 
Psycosocial Considerations in Critical Care 
Care of the Perinatal Patient in Critical Care 
Geriatric Issues in Critical Care 
Conscious Sedation 
************************************************* 
CARDIOVASCULAR SURGERY MODULE 
Monday, September 17,2001, SON Aud, 17th/Chew 
*************************************************** 
FEE: $90.00 PER DAY 





Educational program for RN's who will be assigned 
responsibility to orient new staff to their clinical unit. 
Date Time 
Wed., 8/15/01 0745-1630 






--Please access the Bulletin Board entitled Forms_Nursing. 
-- Select the Cont. Education Registration Form. 
-- Right click on the form and choose "Use Form". 
--Complete all areas (refer to "How To Register" for more 
help on using forms). 
-- Indicate which day you will be attending. 
--Use the comments section to provide us with any additional 
information that may be useful. 
-- We will be unable to process incomplete registrations. 
PennCARE Affiliates and Staff without E-Mail Access 
--Please either call (610-402-2277) or fax (610-402-2203) the 
·following information: name, hospital affiliation, position, 
mailing address, social security#, daytime phone#, and day 
attending. We will be unable to process incomplete 
registrations. 
If you have any questions, please call the Center for Education 
at 610-402-2277. 
Any questions, concerns or comments on articles from CEDS, please contact 
Bonnie Schoeneberger 610-402-2584 
August 
Sun Mon 
5 I 6 



























12 noon - Grand 
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HOSPIT.A..L 
THERAPEUTICS AT A GLANCE 
The following actions were taken at the June 2001 Therapeutics Committee Meeting -Joseph Ottinger R.Ph. MS MBA J · B b R Ph 
Jenny Boucher, Pharm.D. • • • • anme ama y, . ., 
Drug Formulary Issues- Dalteparin, 
Ziprasidone, Bisoprolol 
LMWH (Low Molecular Weight 
Heparin) OVERVIEW: 
The Low Molecular Weight Heparins (LMWH) 
currently available in the U.S. are all 
depolymerized porcine mucosal heparin 
preparations. They are prepared by chemical or 
enzymatic cleavage of the animal source 
heparinoid molecule. These products exhibit 
differences in both their structures and functional 
properties and are not considered interchangeable 
nor have their been any studies comparing these 
agents head-to-head. In addition to effects on AT 
ill (antithrombin ill), factors IIa, Xa, and IXa, 
additional mechanisms of action may mitigate a 
current comparison of anticoagulative properties. 
Other actions identified include the release of 
tissue factor pathway inhibitor (TFPI) ; 
interactions with heparin cofactor IT; inhibition of 
leukocyte procoagulant actions; promotion of 
fibrinolysis; and alteration of protein/ vascular 
endothelium binding sites. 
The three trials most pertinent trails involving 
LMWH in the treatment of unstable/ NSTEMI are 
the FRIC, ESSENCE and TIMI llb trials. All 
ttlese trials compared a LMWH vs unfractionated 
hepariii (UFH). Dalteparin (FRIC) and 
enoxaparin (ESSENCE; TI.MI llb) were the 
agents involved. There are no direct comparisons 
between these two agents. So comparative 
analysis must proceed based on a knowledge of the 
trial methodology, patient populations, definition 
of outcomes, and the clinical significance of those 
outcomes The ESSENCE trial utilized an 
empirical dosage protocol for UFH that was 
supposed to achieve a targeted therapeutic level 
(PTT) within 24 hours. Only half the patients 
enrolled in this arm were in the therapeutic range 
at any point in the study .. In addition, the lack of 
correspondence of PTT and UFH concentrations 
has been fairly well demonstrated in a number of 
papers and has been the primary reason for a 
'push' toward reporting heparin levels. The 
ESSENCE trial utilized 176 different centers each 
using that institutuion's reagent standardization 
procedure. As with pre-INR standardization for 
warfarin therapy, using aPTT values to drive UFH 
dosing may not correlate with therapeutic 
objectives. 
Patients enrolled in both the ESSENCE and TIMI 
llB trials generally were sicker with more patients 
at baseline with NSTEMI, previous MI and more 
patients were protected by ASA at time of 
enrollment. Additionally, the TIMI llB trial 
utilized an IV loading dose of enoxaparin that is 
not currently approved prior to using the lmg/kg 
SC BID regimen and thus confounds combining 
data from the two studies, although a meta analysis 
has been published providing us with this insight. 
Baseline Characteristics: 
FRIC ESSENCE TIM! llB 
NQWMI(%) 16 21 35 
Previous Ml(%) 25 46 32 
ASA users (%) 56 62 84 
The FRIC trial was utilized to gain FDA approval 
for the unstable angina treatment indication, but 
none of its endpoints were statistically significant 
vs. its UFH arm. One mitigating issue identified 
with the trial design was the provision to enroll 
patients up to 72 hours after the initial patient 
presentation (vs. 24 hours for the enoxaparin 
trials). Clearly, the perceived advantage of 
LMWH vs. UFH would be their superior kinetic 
profile resulting in a faster time to therapeutic 
anticoagulation. As mentioned previously, the 
study population was not at as great a risk as the 
enoxaparin populations. Therefore, the relative 
risk reduction would not be expected to be as 
dramatic. 
The elaboration of different primary clinical 
endpoints also confounds a meaningful comparison 
of the various trials. The definition of recurrent 
angina is particularly problematic in assessing the 
outcome points. The FRIC trial defmed it simply 
as chest pain requiring IV nitroglycerin, while 
both ESSENCE and TIMI llB used a more 
detailed assessment parameter of rest angina of at 
least 5 minutes duration, associated with either 
new ST segment shift or T wave inversion; angina 
that prompted revascularization; or post discharge 
angina that prompted re-hospitalization. This is 
particular interest in that the statistically significant 
TEP (triple end-point) was driven primarily by the 
recurrent angina endpoint. Neither of the Death 
nor MI endpoints were statistically significant at 
any point in the analysis. 
Finally, the theoretical benefits of providing 
therapeutic anticoagulant effects earlier in 
treatment (i.e., thrombolytic tx) do appear to favor 
utilization of agents that provide an immediate 
onset of action that can be consistently duplicated 
without intensive monitoring, thus favoring use of 
LMWH. However, the perceived advantage of 
not having to monitor patients on LMWH can 
create a false sense of security related to the nature 
and extent of bleeding. Clinical trials for the 
LMWH have excluded patients with compromised 
renal function; while limited data is available for 
treatment of obese/extremely lean patients . 
Expert recommendations for these patient groups 
range from empiric dosing without monitoring for 
limited duration of therapy to using recommended 
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dosing with follow-up laboratory surveillance 
utilizing anti-factor Xa heparin activity levels or a 
combination of both. 
Fragmin ( dalteparin) is indicated for the 
adjunctive treatment of unstable angina/NSTEMI. 
Its other indications for prophylaxis of DVT/PE 
will not be addressed here. 
CLINICAL PHARMACOLOGY :Dalteparin is a 
low molecular weight heparin analog with a 
molecular weight of 4,000 to 6,000 daltons. 
While dalteparin has been shown to inhibit both 
factor Xa and factor Ila (thrombin), the 
antithrombotic effect of dalteparin is characterized 
by a higher ratio of antifactor Xa to antifactor Ila 
activity. 
ADVERSE REACTIONS: Adverse reactions 
reported with dalteparin therapy include bleeding, 
wound hematoma, injection site hematoma, 
thrombocytopenia, pain at injection site, allergic 
reactions ( eg, pruritus, rash, fever, injection site 
reaction, bulleous eruption), anaphylactoid reactions 
and skin necrosis. 
Hematologic complications that occur with 
dalteparin appear to be dose dependent. Patients 
with severe uncontrolled hypertension, bacterial 
endocarditis, congenital or acquired bleeding 
disorders, active ulceration and angiodysplastic 
gastrointestinal disease, hemorrhagic stroke, or 
shortly after brain, spinal or ophthalmological 
surgery might be at increased risk of hemorrhage. 
Dalteparin therapy is contraindicated in patients 
with known hypersensitivity reactions to heparin, 
pork products or dalteparin. The drug is also 
contraindicated in patients with active major 
bleeding or thrombocytopenia associated with 
positive in vitro tests for antiplatelet antibody in the 
presence of dalteparin. 
RECOMMENDED MONITORING: Because 
dalteparin has a higher ratio of factor Xa:factor Ila 
activity, it does not produce marked increases in 
aPTT and thus, this parameter is not useful. For the 
purpose of clinical investigation, many studies have 
quantified plasma antifactor Xa activity for efficacy 
and safety. In addition, complete blood counts, 
platelet counts and stool occult blood tests should 
be monitored periodically during the course of 
therapy. 
DOSING: Recommended dosing ofdalteparin in 
the treatment of unstable angina/NSTEMI is 120 
units/kg every 12 hours via subcutaneous injection. 
Patients weighing more than 81 kg are 'capped' to a 
dose of 10,000 units every 12 hours. 
This product was approved to the Formulary. An 
autosubstitution was also approved related to initial 
enoxaparin orders for the adjunctive treatment of 
unstable angina/ NSTEMI and anticoagulation 
'bridges' for atrial fibrillation and/or valve 
replacement. A copy of this notice appears below: 
Dear Doctor: 
The Therapeutics Committee has approved an 
autosubstitution for all orders received using 
enoxaparin 'treatment' regimens in patients with 
unstable angina, non ST elevated myocardial 
infarction, or for 'anticoagulation 'bridges' in patients 
with atrial fibrillation or prosthetic valves. These 
orders will be automatically substituted by pharmacy 
to dalteparinl20 units/kg q12h (up to 82 kg) or 
10,000 units (Patients weighing>82 kg) q12h via 
subcutaneous injection. 
ALL doses will be rounded to the closest 100 unit 
dose. Patients with estimated creatinine clearance 
of less than 30ml/min (Cockroft-Gault calculation) will 
not be changed. 
However, use of low molecular weight beparins in 
patients with compromised renal function in 
treatment regimens has not been studied. All 
published data to date have EXCLUDED this patient 
population, therefore no dosing guidelines are 
available to direct therapy in these individuals. There 
are data to suggest that the excretion of LMWHs 
will be reduced in moderate renal failure, leading to 
drug accumulation and a higher risk of bleeding. As 
LMWH's effects on anticoagulation cannot be 
monitored via "standard" laboratory measures, it 
would seem prudent to consider using another 
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agent for anticoagulation. Therapeutic unfractionated 
heparin is generally considered equally effective and 
safe in all indications where treatment regimens of 
low molecular weight heparins are currently 
approved. If you have any questions, please, call 8884 
the Pharmacy department. 
Thank you for your cooperation. 
Geodon (Ziprasidone) is indicated for the 
treatment of schizophrenia. When selecting 
between antipsychotics available for the treatment 
of schizophrenia, the prescriber should consider 
ziprasidone's greater capacity to prolong the 
QT/QTc interval compared to several other agents. 
Prolongation of the QTc interval by other 
medications has been associated with torsades de 
pointes-type arrhythmia and sudden death. It is not 
yet known if ziprasidone will cause torsades de 
pointes or increase the rate of sudden death; 
however, depending on patient circumstances one 
could conclude that another drug should be tried 
first. 
CLINICAL PHARMACOLOGY: Ziprasidone is 
an atypical antipsychotic agent of the 
benzisothiazole class, which structurally resembles 
risperidone (a benzisoxazole). Ziprasidone is a 
combined serotonin and dopamine receptor 
antagonist. It also has activity at the serotonin and 
dopamine transport or re-uptake sites; however, the 
importance of this activity is unknown. 
PHARMACOKINETICS: Peak ziprasidone 
levels are reached within 3 to 8 hours following oral 
administration. Oral bioavailability is 59%. 
Administration with or immediately after a high-fat 
meal increased the mean AUC by 45% to 69% and 
the peak concentration by 40% to 67% Ziprasidone 
is extensively plasma protein bound (>99% ), 
primarily to albumin and a 1-acid glycoprotein. 
Ziprasidone is extensively metabolized by four 
metabolic pathways. CYP3A4 is responsible for the 
primary oxidative metabolites, including the major 
metabolites ziprasidone sulfoxide and ziprasidone 
sulfone. The mean half~life is 7 hours (3.2 to 10 
hours). Less than 5% of the dose is excreted 
unchanged in the urine or feces. Overall, 20% of 
the dose is excreted in the urine and approximately 
66% is excreted in the feces. In patients with mild, 
moderate, or severe renal impairment, the 
pharmacokinetics of ziprasidone did not differ from 
those observed in healthy controls. Hemodialysis 
does not affect the pharmacokinetics of ziprasidone. 
ADVERSE REACTIONS: Side effects in the 
clinical trials have included dyspepsia, constipation, 
nausea, abdominal pain, dry mouth, sedation, 
headache, postural hypotension, dizziness, 
insomnia, akathisia, and rash. Postural hypotension, 
dizziness, and somnolence were more likely to 
occur on the first day of dosing. Asthenia, postural 
hypotension, anorexia, dry mouth, increased 
salivation, arthralgia, anxiety, dizziness, dystonia, 
hypertonia, somnolence, tremor, rhinitis, rash, and 
abnormal vision appeared to be dose related. 
Extrapyramidal effects occurred in 5% of patients. 
Elevated eosinophil levels and elevated 
transaminase levels occurred in a small number of 
ziprasidone-treated patients. 
DRUG INTERACTIONS: Ziprasidone should not 
be administered with any medication that prolongs 
the QT interval. Caution is recommended when 
ziprasidone is administered in combination with 
other centrally acting agents due to the central 
nervous system effects of ziprasidone. Ziprasidone 
may enhance the effects of some antihypertensive 
agents due to its potential for inducing orthostatic 
hypotension. Ziprasidone may antagonize the 
effects of levodopa and dopamine agonists. 
CYP3A4 inhibitors may decrease ziprasidone 
metabolism. 
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DOSING: Ziprasidone therapy should be initiated 
at a dose of 20 mg twice daily with food. The dose 
may subsequently be increased based on response 
up to 80 mg twice daily. Dosage adjustments 
should occur at intervals of not less than 2 days. 
Patients should be observed for improvement for 
several weeks before upward dosage adjustment to 
ensure use of the lowest effective dose. 
To summarize: Ziprasidone is an effective 
antipsychotic with efficacy comparable to 
haloperidol. It has not been associated with weight 
gain, making it unique within this class of 
pharmacologic agents. Ziprasidone has been 
associated with increases in QTc interval, which 
will restrict its use in some populations .. Use of 
other agents that also prolong the QT interval or 
interfere with the metabolism of ziprasadone 
warrants close monitoring. It is available in 20 mg, 
40 mg, 60 mg, and 80 mg capsules; all strengths 
have a drug acquisition cost of $3.1 7 each. This 
strategy places this agent firmly in the 
'middleground' ,as regards drug cost Vs. other 
atypical antipsychotic agents and at higher doses 
may provide some cost advantages. 
Zebeta (Bisoprolol fumarate) is a beta !-
selective ( cardioselective) adrenoreceptor blocking 
agent without significant membrane stabilizing 
activity or intrinsic sympathomimetic activity in its 
therapeutic dosage range. Cardioselectivity is not 
absolute, however, and at higher doses ( 20 mg) 
bisoprolol' fumarate also inhibits beta 2-
adrenoreceptors, chiefly located in the bronchial and 
vascular musculature. 
Bisoprolol is at least as effective in controlling heart 
rate and blood pressure as other marketed beta 
blockers. It also has been shown to have some 
beneficial effects in patients with CHF ( carvedilol 
and metoprolol also have studies suggesting benefit 
in patients with varying degrees of CHF). There are 
a significant number of patients admitted to L VH, 
whose BP is already 'controlled' on this agent or 
f. 
this agent in combination with HCTZ (Ziac). Its 
acquisition cost is comparable to other agents in this 
class (about$ 0.20 per day). Therefore, it was 
recommended by the Therapeutics committee to 
approve the addition of this selective. beta 1 
receptor blocker to the current Formulary. It was 
also recommended that timolol be removed from the 
formulary, as this product provides no advantages 
over other available beta blockers arid has no 
significant level of usage by prescribers at L VH. 
ADR Reports: 
ADR reports have stayed consistent with 71 reports 
in the first quarter of2000. 
Pharmacists and nurses completed about 95% of the 
reports. There has been a large increase in the 
number of reports generated in the outpatient area 
due to newer monoclonal agents. Below is a 
synopsis of the first quarter. 
111 Quarter Data 
Table I : Adverse Reactions By Reporter 
Reporter Reports %Reoorts 
Phannacist 43 60.6 
Nurse 25 35.2 
Physician 1 1.4 
RT 1 1.4 
Student _! 1.4 
TOTAL 71 100 
Table 2 : Adverse Reactions by Drug Category 




Psych/Neurologic Agents . 10 
Narcotic Analgesics 6 














Top 5 Agents by# of Reports 
Cefazolin 6 
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